By Kelvyn Cullimore For the Deseret News
Read More »
Prolaris is the only biomarker test to quantify the benefits…
Recursion has predicted the protein target(s) for approximately 36 billion…
August 7, 2023 Four years ago, Jacob Sheffield was building…
Myriad Genetics announced enhancements to the GeneSight® Psychotropic test.
ComboMATCH study uses genetic testing to match advanced cancer patients…
World leading, multi-disciplinary experts advise on adoption of FDA authorized…
SOUTH JORDAN, Utah, Aug. 03, 2023 (GLOBE NEWSWIRE) — Merit…
U.S. FDA Grants an Investigational Device Exemption for Trial Evaluating…
Quansys Biosciences and The Michael J. Fox Foundation, announced a…
New Study Details Proposed Federal Government-Mandated Drug Pricing Policies Senate…
Valence Labs is Recursion’s new machine learning research center that…
A new system for fixing bone fractures, called the Bone…
LEHI, Utah–(BUSINESS WIRE)– Owlet, Inc. (“Owlet” or the “Company”) (NYSE:…
RiskScore is the first validated risk model that includes breast…
BD Alaris™ Infusion System is the only modular and most…
Distribution agreement opens kidneyintelX.dkd testing to address early-stage kidney disease…
LEHI, Utah–(BUSINESS WIRE)– Owlet, Inc. (NYSE: OWLT, “the Company”), the…
The Company intends to use the funds awarded by the…
The Company intends to use funds awarded by the Bill…
Notifications
